Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/12702
Title: | Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE |
Authors: | Greenhalgh, J Longworth, L Crossan, C Singh, J Bagust, A Beale, S Richardson, M Banks, L Kotas, E Hall, M |
Keywords: | Guidance;Edoxaban;Stroke;Prevention;Systemic embolism |
Issue Date: | 2015 |
Publisher: | National Institute for Health and Care Excellence (NICE) |
Citation: | Greenhalgh, J., Longworth, L., Crossan, C., Singh, J., Bagust, A., Beale, S., Richardson, M., Banks, L., Kotas, E. and Hall, M. (September 2015) 'Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICE', NICE technology appraisal guidance (TA355), pp. 1 - 40. ISBN: 978-1-4731-1440-1. |
Abstract: | 1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, including: congestive heart failure hypertension diabetes prior stroke or transient ischaemic attack age 75 years or older. |
URI: | https://bura.brunel.ac.uk/handle/2438/12702 |
ISBN: | 978-1-4731-1440-1 |
Appears in Collections: | Health Economics Research Group (HERG) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 232.75 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.